Last reviewed · How we verify

AMG 301 — Competitive Intelligence Brief

AMG 301 (AMG 301) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: IL-1 receptor antagonist. Area: Oncology.

phase 2 IL-1 receptor antagonist IL1R1 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

AMG 301 (AMG 301) — Amgen. AMG 301 is a monoclonal antibody targeting the interleukin-1 receptor type 1 (IL1R1).

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
AMG 301 TARGET AMG 301 Amgen phase 2 IL-1 receptor antagonist IL1R1
Anakinra (r-metHuIL-1ra) Anakinra (r-metHuIL-1ra) Amgen marketed IL-1 receptor antagonist IL-1 receptor type I (IL-1RI)
Anakinra (Kineret®) Anakinra (Kineret®) Monash Medical Centre phase 3 IL-1 receptor antagonist IL-1 receptor type I

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (IL-1 receptor antagonist class)

  1. Amgen · 2 drugs in this class
  2. Monash Medical Centre · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AMG 301 — Competitive Intelligence Brief. https://druglandscape.com/ci/amg-301. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: